HIV Acquisition Is Associated with Increased Antimicrobial Peptides and Reduced HIV Neutralizing IgA in the Foreskin Prepuce of Uncircumcised Men

English version České info

Randomized trials of male circumcision (MC) for HIV prevention have shown that the foreskin is a major site of HIV acquisition among heterosexual men, but a number of barriers to MC programs mean that many HIV-susceptible men remain uncircumcised. The immune correlates of HIV acquisition in the foreskin are poorly described, and may inform prevention strategies for uncircumcised men. Using swabs collected prospectively during a previous randomized trial of MC for HIV prevention in Uganda, blinded investigators assessed levels of HIV-neutralizing IgA and soluble antimicrobial peptides in the foreskin prepuce of cases who acquired HIV (n = 99) and controls men who did not (n = 109). We show that IgA with the capacity to neutralize HIV was associated with protection against HIV, while levels of α-defensins and secretory leukocyte protease inhibitor (SLPI) were associated with increased acquisition. This is the first study to assess the immune correlates of HIV acquisition in the foreskin. Advantages included its relatively large sample size, rigorous blinding of immune assays, and ability to control for relevant potential confounders.

Vyšlo v časopise: HIV Acquisition Is Associated with Increased Antimicrobial Peptides and Reduced HIV Neutralizing IgA in the Foreskin Prepuce of Uncircumcised Men. PLoS Pathog 10(10): e32767. doi:10.1371/journal.ppat.1004416
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004416

Souhrn

Zdroje

1. AndersonD, PolitchJA, PudneyJ (2011) HIV infection and immune defense of the penis. Am J Reprod Immunol 65: 220–229.

2. AuvertB, TaljaardD, LagardeE, Sobngwi-TambekouJ, SittaR, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298.

3. BaileyRC, MosesS, ParkerCB, AgotK, MacleanI, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643–656.

4. GrayRH, KigoziG, SerwaddaD, MakumbiF, WatyaS, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657–666.

5. DinhMH, FahrbachKM, HopeTJ (2011) The role of the foreskin in HIV transmission: an evidence-based review. Am J Reprod Immunol 65: 279–283.

6. DonovalBA, LandayAL, MosesS, AgotK, Ndinya-AcholaJO, et al. (2006) HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 125: 386–391.

7. FischettiL, BarrySM, HopeTJ, ShattockRJ (2009) HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS 23: 319–328.

8. GanorY, BomselM (2011) HIV-1 transmission in the male genital tract. Am J Reprod Immunol 65: 284–291.

9. GanorY, ZhouZ, TudorD, SchmittA, Vacher-LavenuMC, et al. (2010) Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol 3: 506–522.

10. JohnsonKE, ShermanME, SsempiijaV, TobianAA, ZenilmanJM, et al. (2009) Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 23: 1807–1815.

11. ProdgerJL, GrayR, KigoziG, NalugodaF, GaliwangoR, et al. (2012) Impact of asymptomatic Herpes simplex virus-2 infection on T cell phenotype and function in the foreskin. AIDS 26: 1319–1322.

12. QinQ, ZhengXY, WangYY, ShenHF, SunF, et al. (2009) Langerhans' cell density and degree of keratinization in foreskins of Chinese preschool boys and adults. Int Urol Nephrol 41: 747–753.

13. ZhouZ, Barry de LongchampsN, SchmittA, ZerbibM, Vacher-LavenuMC, et al. (2011) HIV-1 efficient entry in inner foreskin is mediated by elevated CCL5/RANTES that recruits T cells and fuels conjugate formation with Langerhans cells. PLoS Pathog 7: e1002100.

14. BoilyMC, BaggaleyRF, WangL, MasseB, WhiteRG, et al. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9: 118–129.

15. PowersKA, PooleC, PettiforAE, CohenMS (2008) Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 8: 553–563.

16. IqbalSM, KaulR (2008) Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 59: 44–54.

17. ColeAM (2005) Antimicrobial peptide microbicides targeting HIV. Protein Pept Lett 12: 41–47.

18. ColeAM, ColeAL (2008) Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 59: 27–34.

19. ChangTL, VargasJJr, DelPortilloA, KlotmanME (2005) Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115: 765–773.

20. MackewiczCE, YuanJ, TranP, DiazL, MackE, et al. (2003) alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. Aids 17: F23–32.

21. BergmanP, Walter-JallowL, BrolidenK, AgerberthB, SoderlundJ (2007) The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res 5: 410–415.

22. MaG, Greenwell-WildT, LeiK, JinW, SwisherJ, et al. (2004) Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 200: 1337–1346.

23. PorterE, YangH, YavagalS, PrezaGC, MurilloO, et al. (2005) Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun 73: 4823–4833.

24. PudneyJ, AndersonD (2011) Innate and acquired immunity in the human penile urethra. J Reprod Immunol 88: 219–227.

25. ProdgerJL, HirbodT, KigoziG, NalugodaF, ReynoldsSJ, et al. (2014) Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda. Mucosal Immunol 7: 634–644.

26. LevinsonP, KaulR, KimaniJ, NgugiE, MosesS, et al. (2009) Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 23: 309–317.

27. HasselrotK, SabergP, HirbodT, SoderlundJ, EhnlundM, et al. (2009) Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 23: 329–333.

28. ChoiRY, LevinsonP, GuthrieBL, Lohman-PayneB, BosireR, et al. (2012) Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS 26: 2155–2163.

29. DevitoC, BrolidenK, KaulR, SvenssonL, JohansenK, et al. (2000) Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 165: 5170–5176.

30. HirbodT, BrolidenK, KaulR (2008) Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. AIDS 22: 2401–2402.

31. FioreJR, LaddagoV, LeperaA, La GrastaL, Di StefanoM, et al. (2000) Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol 23: 85–92.

32. HortonRE, BallTB, WachichiC, JaokoW, RutherfordWJ, et al. (2009) Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses 25: 83–92.

33. HirbodT, KaulR, ReichardC, KimaniJ, NgugiE, et al. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22: 727–735.

34. O'FarrellN, ChungCK, WeissHA (2008) Foreskin length in uncircumcised men is associated with subpreputial wetness. Int J STD AIDS 19: 821–823.

35. O'FarrellN, MorisonL, MoodleyP, PillayK, VanmaliT, et al. (2006) Association between HIV and subpreputial penile wetness in uncircumcised men in South Africa. J Acquir Immune Defic Syndr 43: 69–77.

36. JohanssonM, LyckeNY (2003) Immunology of the human genital tract. Curr Opin Infect Dis 16: 43–49.

37. PudneyJ, AndersonDJ (1995) Immunobiology of the human penile urethra. Am J Pathol 147: 155–165.

38. BelecL, GhysPD, HociniH, NkengasongJN, Tranchot-DialloJ, et al. (2001) Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 184: 1412–1422.

39. BomselM, PastoriC, TudorD, AlbertiC, GarciaS, et al. (2007) Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS 21: 13–22.

40. ClericiM, BarassiC, DevitoC, PastoriC, PiconiS, et al. (2002) Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. Aids 16: 1731–1741.

41. LopalcoL, BarassiC, PastoriC, LonghiR, BurasteroSE, et al. (2000) CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol 164: 3426–3433.

42. MesteckyJ, WrightPF, LopalcoL, StaatsHF, KozlowskiPA, et al. (2011) Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 27: 469–486.

43. KaleebuP, WhitworthJ, HamiltonL, RutebemberwaA, LyagobaF, et al. (2000) Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda. AIDS Res Hum Retroviruses 16: 393–401.

44. YirrellDL, KaleebuP, MorganD, WateraC, MagamboB, et al. (2002) Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS 16: 279–286.

45. FurciL, SironiF, TolazziM, VassenaL, LussoP (2007) Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 109: 2928–2935.

46. WangW, OwenSM, RudolphDL, ColeAM, HongT, et al. (2004) Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 173: 515–520.

47. ChertovO, MichielDF, XuL, WangJM, TaniK, et al. (1996) Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 271: 2935–2940.

48. KaulR, BallTB, HirbodT (2011) Defining the genital immune correlates of protection against HIV acquisition: co-infections and other potential confounders. Sex Transm Infect 87: 125–130.

49. KaulR, RebbapragadaA, HirbodT, WachihiC, BallTB, et al. (2008) Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS 22: 2049–2051.

50. TudorD, YuH, MaupetitJ, DrilletAS, BoucebaT, et al. (2012) Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A 109: 12680–12685.

51. WatkinsJD, SholukhAM, MukhtarMM, SiddappaNB, LakhasheSK, et al. (2013) Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27: F13–20.

52. LizengQ, SkottP, SourialS, NilssonC, AnderssonSS, et al. (2003) Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 308: 225–232.

53. HirbodT, KaulR, ReichardC, KimaniJ, NgugiE, et al. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22: 727–735.

54. SoderlundJ, HirbodT, GohLE, AnderssonJ, BrolidenK (2004) Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients. Scand J Infect Dis 36: 663–669.